LC-MS/MS determination of Synercid® injections

被引:23
作者
Abdel-Hamid, ME [1 ]
Phillips, OA [1 ]
机构
[1] Kuwait Univ, Hlth Sci Ctr, Fac Pharm, Dept Pharmaceut Chem, Safat 13110, Kuwait
关键词
Synercid((R)); quinupristin; dalfopristin; LC-MS/MS;
D O I
10.1016/S0731-7085(03)00231-0
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Synercid(R) is a combination of two semisynthetic pristinamycin derivatives, quinupristin and dalfopristin in 30:70 (w/w) ratio. A rapid and specific high-performance liquid chromatography-mass spectrometry was developed for the determination of quinupristin and dalfopristin using positive electrospray tandem mass spectrometry (+ESI-MS/MS). Multiple reaction monitoring transitions at 1023.05 > 134.34 and 691.87 > 166.26 were selected for the quantitation of quinupristin and dalfopristin, respectively. The assay run cycle-time was similar to 2.0 min injection-to-injection. The assay was linear up to concentration of 4000 ng ml(-1) quinupristin and 1920 ng ml(-1) dalfopristin. The lowest limits of quantitation of quinupristin and dalfopristin were found to be 1000 and 480 ng ml(-1), respectively. Quantitation was based on peak area measurement of quinupristin and dalfopristin using weighed linear regression. Linear relationships with correlation coefficients (r>0.99) were automatically computed for both constituents by MASSLYNX quantify program. The ratio of the slopes of the calibration curves of quinupristin and dalfopristin was found to be 0.425, which matches the nominal ratio composition of the antimicrobial compounds in Synercid(R). The %RSD ranges were 2.3-4.0% for dalfopristin and 1.3-4.2% for quinupristin, whereas the %DEV ranges were (-7.5+3.7) and (-1.2+9.1%), respectively, indicating appropriate precision and accuracy. Recoveries of 99.5-103.8% and 97.8-99.0% of quinupristin and dalfopristin, respectively, were computed from Synercid(R) injection. The described method is recommended for rapid determination of the contents and for tracking the stability and compatibility of quinupristin and dalfopristin in Synercid(R)injection. (C) 2003 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:1167 / 1174
页数:8
相关论文
共 10 条
[1]   Liquid chromatographic-mass spectrometric determination of celecoxib in plasma using single-ion monitoring and its use in clinical pharmacokinetics [J].
Abdel-Hamid, M ;
Novotny, L ;
Hamza, H .
JOURNAL OF CHROMATOGRAPHY B, 2001, 753 (02) :401-408
[2]   High-performance liquid chromatography-mass spectrometric analysis of furosemide in plasma and its use in pharmacokinetic studies [J].
Abdel-Hamid, ME .
FARMACO, 2000, 55 (6-7) :448-454
[3]   Stability study of the anticonvulsant enaminone (E118) using HPLC and LC-MS [J].
Abdel-Hamid, ME ;
Edafiogho, IO ;
Hamza, HM .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2002, 27 (1-2) :225-234
[4]   Synthesis, spectroscopic characterization, stability assessment and DNA-binding of new 2,6-piperidinedione derivatives [J].
Abou-Zeid, L ;
El-Mowafy, AM ;
El-Kerdawy, MM ;
Hamza, H ;
Abdel-Hamid, ME .
FARMACO, 2001, 56 (10) :763-770
[5]   PHARMACOKINETICS AND SUCTION BLISTER FLUID PENETRATION OF A SEMISYNTHETIC INJECTABLE STREPTOGRAMIN RP-59500 (RP-57669 RP-54476) [J].
BERNARD, E ;
BENSOUSSAN, M ;
BENSOUSSAN, F ;
ETIENNE, S ;
CAZENAVE, I ;
CARSENTIETESSE, E ;
LEROUX, Y ;
MONTAY, G ;
DELLAMONICA, P .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1994, 13 (09) :768-771
[6]   Simultaneous high-performance liquid chromatographic determination of quinupristin, dalfopristin and their main metabolites in human plasma [J].
Le Liboux, A ;
Pasquier, O ;
Montay, G .
JOURNAL OF CHROMATOGRAPHY B, 1998, 708 (1-2) :161-168
[7]  
Nakashio Satoshi, 1997, Japanese Journal of Antibiotics, V50, P844
[8]  
Novotny L, 2002, PHARMAZIE, V57, P252
[9]   Determination of linezolid in human plasma by LC-MS-MS [J].
Phillips, OA ;
Abdel-Hamid, ME ;
Al-Hassawi, NA .
ANALYST, 2001, 126 (05) :609-614
[10]   Development and validation of a high-performance liquid chromatographic stability-indicating method for the analysis of Synercid® in quality control, stability and compatibility studies [J].
Vasselle, B ;
Gousset, G ;
Bounine, JP .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1999, 19 (05) :641-657